ReVision Optics is a technology company.
ReVision Optics has raised $182.0M across 8 funding rounds.
ReVision Optics has raised $182.0M in total across 8 funding rounds.
ReVision Optics has raised $182.0M in total across 8 funding rounds.
ReVision Optics's investors include Canaan Partners, Domain Associates, InterWest, Johnson & Johnson Innovation, Lightstone Ventures, Santé Ventures, Venrock, Wildcat Ventures, Stephen Oesterle.
ReVision Optics is a medical device company specializing in innovative optical solutions for presbyopia, an age-related vision condition affecting near vision.[2][3][5] It developed the Raindrop Near Vision Inlay, a tiny implantable corneal inlay resembling a contact lens that reshapes the cornea to restore near vision without glasses or contacts, targeting patients over 45 with a potential U.S. market of 30 million.[3][5][6] The company serves ophthalmologists and presbyopia patients, solving the problem of age-related reading difficulties by offering a minimally invasive, reversible alternative to traditional corrections; it achieved FDA approval in June 2016 and launched commercially in the U.S. shortly after, backed by over $165 million in equity funding plus debt.[3][6]
Growth momentum included a $32 million round in 2017 led by Johnson & Johnson Development Corporation (JJDC), with participation from Canaan Partners, Domain Associates, Interwest Partners, and Proquest Investments, to fuel marketing, commercialization, and medical affairs expansion following its Series E in 2013.[3]
Founded in 1996, ReVision Optics emerged to tackle presbyopia through advanced implantable optics, with early focus on corneal inlay technology.[3] Key leadership included John Kilcoyne as president and CEO, who highlighted the company's strong venture backing in 2017 announcements.[3] The idea stemmed from addressing the limitations of glasses and contacts for presbyopia, leading to the Raindrop inlay's development over two decades; pivotal moments were FDA approval in June 2016 and the first U.S. commercial cases announced post-launch, marking a shift from R&D to market entry.[3][6] Prior funding, including a $55 million Series E in 2013 with JJDC and others, built toward this commercialization phase.[3]
ReVision Optics rides the wave of presbyopia treatment innovation, a booming ophthalmology sector driven by aging populations (e.g., Baby Boomers and beyond) facing vision decline, with market forces like rising demand for spectacle-free solutions favoring corneal inlays over lasers or drops.[2][3][5] Timing was ideal post-2016 FDA nod, aligning with advances in minimally invasive eye tech amid a $10+ billion global presbyopia market. It influences the ecosystem by validating implantable optics, paving the way for surgeon adoption and investor interest in medtech startups targeting age-related conditions, though competition from pharma drops and rivals tests its niche.[3][5]
ReVision Optics' trajectory hinges on scaling Raindrop adoption amid post-launch commercialization, potentially expanding globally if U.S. traction builds on early cases.[3][6] Trends like personalized ophthalmology, AI-driven diagnostics, and combination therapies (e.g., with drops) could amplify its role, but challenges include reimbursement hurdles and emerging non-implant competitors. Its influence may evolve toward acquisitions by big pharma/ophthalmology firms like Johnson & Johnson, leveraging JJDC ties, solidifying its legacy in presbyopia innovation from a 1996 startup to market pioneer.[3] This positions it as a key player in vision correction's shift to implants, echoing its core mission of transformative optics.[2]
ReVision Optics has raised $182.0M across 8 funding rounds. Most recently, it raised $32.0M Venture Round in November 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2016 | $32.0M Venture Round | Canaan Partners, Domain Associates, InterWest, Johnson & Johnson Innovation, Lightstone Ventures, Santé Ventures, Venrock, Wildcat Ventures, Stephen Oesterle | |
| Jul 1, 2013 | $55.0M Series E | Canaan Partners, Domain Associates, InterWest, Johnson & Johnson Innovation, Lightstone Ventures, Santé Ventures, Venrock, Wildcat Ventures, Stephen Oesterle | |
| Apr 1, 2013 | $15.0M Series E | Canaan Partners, Domain Associates, InterWest, Johnson & Johnson Innovation, Lightstone Ventures, Santé Ventures, Venrock, Wildcat Ventures, Stephen Oesterle | |
| Jul 1, 2010 | $35.0M Series D | Canaan Partners, Domain Associates, InterWest, Johnson & Johnson Innovation, Wildcat Ventures | |
| Apr 1, 2007 | $25.0M Series D | Canaan Partners, Domain Associates, InterWest, Johnson & Johnson Innovation, Wildcat Ventures | |
| Jun 1, 2006 | $3.0M Series C | Canaan Partners, InterWest, Wildcat Ventures | |
| Oct 1, 2005 | $12.0M Series C | Canaan Partners | |
| Dec 1, 2004 | $5.0M Series C | Canaan Partners |